BACKGROUND: Clinical evidence that ketamine, a nonselective N-methyl-D-aspartate receptor (NMDAR) antagonist, has therapeutic effects within hours in people suffering from depression suggests that modulating glutamatergic neurotransmission is a fundamental step in alleviating the debilitating symptoms of mood disorders. Acutely, ketamine increases extracellular glutamate levels, neuronal excitability, and spontaneous γ oscillations, but it is unknown whether these effects are key to the mechanism of antidepressant action of ketamine. METHODS: Twenty drug-free major depressive disorder patients received a single, open-label intravenous infusion of ketamine hydrochloride (.5 mg/kg). Magnetoencephalographic recordings were made approximately 3 days before and approximately 6.5 hours after the infusion, whereas patients passively received tactile stimulation to the right and left index fingers and also while they rested (eyes-closed). Antidepressant response was assessed by percentage change in Montgomery-Åsberg Depression Rating Scale scores. RESULTS: Patients with robust improvements in depressive symptoms 230 min after infusion (responders) exhibited increased cortical excitability within this antidepressant response window. Specifically, we found that stimulus-evoked somatosensory cortical responses increase after infusion, relative to pretreatment responses in responders but not in treatment nonresponders. Spontaneous somatosensory cortical γ-band activity during rest did not change within the same timeframe after ketamine in either responders or nonresponders. CONCLUSIONS: These findings suggest NMDAR antagonism does not lead directly to increased cortical excitability hours later and thus might not be sufficient for therapeutic effects of ketamine to take hold. Rather, increased cortical excitability as depressive symptoms improve is consistent with the hypothesis that enhanced non-NMDAR-mediated glutamatergic neurotransmission via synaptic potentiation is central to the antidepressant effect of ketamine.
BACKGROUND: Clinical evidence that ketamine, a nonselective N-methyl-D-aspartate receptor (NMDAR) antagonist, has therapeutic effects within hours in people suffering from depression suggests that modulating glutamatergic neurotransmission is a fundamental step in alleviating the debilitating symptoms of mood disorders. Acutely, ketamine increases extracellular glutamate levels, neuronal excitability, and spontaneous γ oscillations, but it is unknown whether these effects are key to the mechanism of antidepressant action of ketamine. METHODS: Twenty drug-free major depressive disorderpatients received a single, open-label intravenous infusion of ketamine hydrochloride (.5 mg/kg). Magnetoencephalographic recordings were made approximately 3 days before and approximately 6.5 hours after the infusion, whereas patients passively received tactile stimulation to the right and left index fingers and also while they rested (eyes-closed). Antidepressant response was assessed by percentage change in Montgomery-Åsberg Depression Rating Scale scores. RESULTS:Patients with robust improvements in depressive symptoms 230 min after infusion (responders) exhibited increased cortical excitability within this antidepressant response window. Specifically, we found that stimulus-evoked somatosensory cortical responses increase after infusion, relative to pretreatment responses in responders but not in treatment nonresponders. Spontaneous somatosensory cortical γ-band activity during rest did not change within the same timeframe after ketamine in either responders or nonresponders. CONCLUSIONS: These findings suggest NMDAR antagonism does not lead directly to increased cortical excitability hours later and thus might not be sufficient for therapeutic effects of ketamine to take hold. Rather, increased cortical excitability as depressive symptoms improve is consistent with the hypothesis that enhanced non-NMDAR-mediated glutamatergic neurotransmission via synaptic potentiation is central to the antidepressant effect of ketamine.
Authors: A Maksimow; M Särkelä; J W Långsjö; E Salmi; K K Kaisti; A Yli-Hankala; S Hinkka-Yli-Salomäki; H Scheinin; S K Jääskeläinen Journal: Clin Neurophysiol Date: 2006-06-27 Impact factor: 3.708
Authors: A Le Liboux; P Lefebvre; Y Le Roux; P Truffinet; M Aubeneau; S Kirkesseli; G Montay Journal: J Clin Pharmacol Date: 1997-09 Impact factor: 3.126
Authors: P V Choudary; M Molnar; S J Evans; H Tomita; J Z Li; M P Vawter; R M Myers; W E Bunney; H Akil; S J Watson; E G Jones Journal: Proc Natl Acad Sci U S A Date: 2005-10-17 Impact factor: 11.205
Authors: R Bernard; I A Kerman; R C Thompson; E G Jones; W E Bunney; J D Barchas; A F Schatzberg; R M Myers; H Akil; S J Watson Journal: Mol Psychiatry Date: 2010-04-13 Impact factor: 15.992
Authors: Lindsay Rutter; Frederick W Carver; Tom Holroyd; Sreenivasan Rajamoni Nadar; Judy Mitchell-Francis; Jose Apud; Daniel R Weinberger; Richard Coppola Journal: Hum Brain Mapp Date: 2009-10 Impact factor: 5.038
Authors: Sheldon H Preskorn; Bryan Baker; Sheela Kolluri; Frank S Menniti; Michael Krams; Jaren W Landen Journal: J Clin Psychopharmacol Date: 2008-12 Impact factor: 3.153
Authors: Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji Journal: Biol Psychiatry Date: 2007-07-23 Impact factor: 13.382
Authors: Anita E Autry; Megumi Adachi; Elena Nosyreva; Elisa S Na; Maarten F Los; Peng-fei Cheng; Ege T Kavalali; Lisa M Monteggia Journal: Nature Date: 2011-06-15 Impact factor: 49.962
Authors: Mark J Niciu; Ioline D Henter; David A Luckenbaugh; Carlos A Zarate; Dennis S Charney Journal: Annu Rev Pharmacol Toxicol Date: 2014 Impact factor: 13.820
Authors: Jonathan Fischell; Adam M Van Dyke; Mark D Kvarta; Tara A LeGates; Scott M Thompson Journal: Neuropsychopharmacology Date: 2015-04-22 Impact factor: 7.853
Authors: Amy Badura-Brack; Timothy J McDermott; Elizabeth Heinrichs-Graham; Tara J Ryan; Maya M Khanna; Daniel S Pine; Yair Bar-Haim; Tony W Wilson Journal: Biol Psychol Date: 2018-01-05 Impact factor: 3.251
Authors: Jessica R Gilbert; Elizabeth D Ballard; Christina S Galiano; Allison C Nugent; Carlos A Zarate Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2019-12-03